TuHURA Biosciences (HURA) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed TuHURA Biosciences (HURA) over the past year, gaining 9.4% versus a loss of 24.0%. Over five years, PMVP leads with a -93.7% price change compared with -99.9% for HURA. TuHURA Biosciences is the larger company by market cap ($124.9 million vs $114.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | PMVP |
|---|---|---|
| Share price | $1.96 | $1.52 |
| Market cap | $124.90M | $114.78M |
| 1-day change | +1.55% | +2.01% |
| YTD return | +158.92% | +21.60% |
| 1-year return | -24.03% | +9.35% |
| 5-year return | -99.87% | -93.66% |
| EPS (TTM) | $-0.54 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.43 | $1.91 |
| 52-week low | $0.41 | $1.02 |
| Distance from 52-week high | -42.86% | -20.42% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +310.20% | +176.32% |
| Average volume | 244.46K | 672.63K |
| Shares outstanding | 63.73M | 75.51M |
| Employees | 22 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed HURA by 33.4 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
HURA vs PMVP FAQ
Which is bigger, TuHURA Biosciences or PMV Pharmaceuticals?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $124.90M compared with $114.78M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, HURA or PMVP?
PMVP returned +9.35% over the past 12 months, compared with -24.03% for HURA (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.